https://nanets.net/abstracts-archive?format=html Mon, 26 Jan 2026 00:00:00 -0500 en-GB hourly 1 https://nanets.net/abstracts-archive/2025/2223-c25-fidelman-poster-safety-of-transarterial-liver-directed-therapy-for-metastatic-neuroendocrine-tumor-for-patients-with-carcinoid-heart-disease?format=html [C25] Fidelman (POSTER) - Safety of Transarterial Liver Directed Therapy for Metastatic Neuroendocrine Tumor for Patients with Carcinoid Heart Disease https://nanets.net/abstracts-archive/2025/2223-c25-fidelman-poster-safety-of-transarterial-liver-directed-therapy-for-metastatic-neuroendocrine-tumor-for-patients-with-carcinoid-heart-disease?format=html thompsonm@adgcommunications.com ( Michael Thompson) 2025 Mon, 26 Jan 2026 00:00:00 -0500 https://nanets.net/abstracts-archive/2025/2222-b2-gillis-poster-validation-of-adversity-linked-genes-in-pancreatic-neuroendocrine-tumors?format=html [B2] Gillis (POSTER) - Validation of Adversity Linked Genes in Pancreatic Neuroendocrine Tumors https://nanets.net/abstracts-archive/2025/2222-b2-gillis-poster-validation-of-adversity-linked-genes-in-pancreatic-neuroendocrine-tumors?format=html gibsonc@adgcommunications.com (Cassandra Gibson) 2025 Tue, 16 Dec 2025 10:41:57 -0500 https://nanets.net/abstracts-archive/2025/2221-o5-graboyes-poster-recurrent-tympanic-paragangliomas-an-overview-of-institutional-experience?format=html [O5] Graboyes (POSTER) - Recurrent Tympanic Paragangliomas An Overview of Institutional Experience https://nanets.net/abstracts-archive/2025/2221-o5-graboyes-poster-recurrent-tympanic-paragangliomas-an-overview-of-institutional-experience?format=html gibsonc@adgcommunications.com (Cassandra Gibson) 2025 Tue, 16 Dec 2025 10:39:37 -0500 https://nanets.net/abstracts-archive/2025/2220-c18-tesfaye-poster-patient-characteristics-and-treatment-patterns-with-177lu-lu-dota-tate-177lu-dotatate-in-the-us-a-real-world-assessment?format=html [C18] Tesfaye (POSTER) - Patient Characteristics and Treatment Patterns With [177Lu]Lu DOTA TATE (177Lu DOTATATE) In the US A Real World Assessment https://nanets.net/abstracts-archive/2025/2220-c18-tesfaye-poster-patient-characteristics-and-treatment-patterns-with-177lu-lu-dota-tate-177lu-dotatate-in-the-us-a-real-world-assessment?format=html gibsonc@adgcommunications.com (Cassandra Gibson) 2025 Tue, 16 Dec 2025 10:36:32 -0500 https://nanets.net/abstracts-archive/2025/2219-t12-pruitt-poster-a-prospective-observational-study-of-glp-1-and-glp-1-gip-receptor-agonists-in-patients-with-well-differentiated-neuroendocrine-tumors?format=html [T12] Pruitt (POSTER) - A Prospective Observational Study of GLP 1 and GLP 1 GIP Receptor Agonists in Patients with Well Differentiated Neuroendocrine Tumors https://nanets.net/abstracts-archive/2025/2219-t12-pruitt-poster-a-prospective-observational-study-of-glp-1-and-glp-1-gip-receptor-agonists-in-patients-with-well-differentiated-neuroendocrine-tumors?format=html gibsonc@adgcommunications.com (Cassandra Gibson) 2025 Tue, 16 Dec 2025 10:31:58 -0500 https://nanets.net/abstracts-archive/2025/2218-c12-soulen-poster-randomized-embolization-trial-for-neuroendocrine-tumors-retnet?format=html [C12] Soulen (POSTER) - Randomized Embolization Trial for NeuroEndocrine Tumors (RETNET) https://nanets.net/abstracts-archive/2025/2218-c12-soulen-poster-randomized-embolization-trial-for-neuroendocrine-tumors-retnet?format=html gibsonc@adgcommunications.com (Cassandra Gibson) 2025 Tue, 16 Dec 2025 10:29:54 -0500 https://nanets.net/abstracts-archive/2025/2217-c13-thuemmler-poster-safety-and-clinical-implications-of-concurrent-biopsy-of-neuroendocrine-liver-metastases-at-the-time-of-liver-directed-therapy?format=html [C13] Thuemmler (POSTER) - Safety and clinical implications of concurrent biopsy of neuroendocrine liver metastases at the time of liver directed therapy https://nanets.net/abstracts-archive/2025/2217-c13-thuemmler-poster-safety-and-clinical-implications-of-concurrent-biopsy-of-neuroendocrine-liver-metastases-at-the-time-of-liver-directed-therapy?format=html gibsonc@adgcommunications.com (Cassandra Gibson) 2025 Tue, 16 Dec 2025 10:28:54 -0500 https://nanets.net/abstracts-archive/2025/2216-t6-soulen-poster-multicenter-phase-2-trial-of-yttrium-90-radioembolization-with-capecitabine-temozolomide-for-grade-2-liver-dominant-metastatic-neuroendocrine-tumors-interim-report?format=html [T6] Soulen (POSTER) - Multicenter Phase 2 Trial of Yttrium 90 Radioembolization with Capecitabine Temozolomide for Grade 2 Liver Dominant Metastatic Neuroendocrine Tumors interim report https://nanets.net/abstracts-archive/2025/2216-t6-soulen-poster-multicenter-phase-2-trial-of-yttrium-90-radioembolization-with-capecitabine-temozolomide-for-grade-2-liver-dominant-metastatic-neuroendocrine-tumors-interim-report?format=html gibsonc@adgcommunications.com (Cassandra Gibson) 2025 Tue, 16 Dec 2025 10:27:48 -0500 https://nanets.net/abstracts-archive/2025/2215-c27-chauhan-poster-efficacy-and-safety-of-peptide-receptor-radionuclide-therapy-retreatment-r-prrt-practices-in-progressive-neuroendocrine-tumors-prog-nets-systematic-review-and-meta-analysis?format=html [C27] Chauhan (POSTER) - Efficacy and Safety of Peptide Receptor Radionuclide Therapy Retreatment (r PRRT) Practices in Progressive Neuroendocrine Tumors (prog NETs) Systematic Review and Meta Analysis https://nanets.net/abstracts-archive/2025/2215-c27-chauhan-poster-efficacy-and-safety-of-peptide-receptor-radionuclide-therapy-retreatment-r-prrt-practices-in-progressive-neuroendocrine-tumors-prog-nets-systematic-review-and-meta-analysis?format=html gibsonc@adgcommunications.com (Cassandra Gibson) 2025 Tue, 16 Dec 2025 10:26:31 -0500 https://nanets.net/abstracts-archive/2025/2214-p8-paciorek-poster-clinical-details-of-early-onset-neuroendocrine-neoplasms-differ-by-race-and-ethnicity-and-overall-differ-from-typical-onset?format=html [P8] Paciorek (POSTER) - Clinical details of early onset neuroendocrine neoplasms differ by race and ethnicity and overall differ from typical onset https://nanets.net/abstracts-archive/2025/2214-p8-paciorek-poster-clinical-details-of-early-onset-neuroendocrine-neoplasms-differ-by-race-and-ethnicity-and-overall-differ-from-typical-onset?format=html gibsonc@adgcommunications.com (Cassandra Gibson) 2025 Tue, 16 Dec 2025 10:25:18 -0500 https://nanets.net/abstracts-archive/2025/2213-c21-ali-poster-single-institution-experience-with-131i-mibg-for-pheochromocytoma-and-paraganglioma-long-term-outcomes-and-dosimetry?format=html [C21] Ali (POSTER) - Single institution experience with [131I]MIBG for pheochromocytoma and paraganglioma Long term outcomes and dosimetry https://nanets.net/abstracts-archive/2025/2213-c21-ali-poster-single-institution-experience-with-131i-mibg-for-pheochromocytoma-and-paraganglioma-long-term-outcomes-and-dosimetry?format=html gibsonc@adgcommunications.com (Cassandra Gibson) 2025 Tue, 16 Dec 2025 10:24:15 -0500 https://nanets.net/abstracts-archive/2025/2212-o2-estrada-poster-analysis-of-patient-selection-for-germline-testing-in-early-onset-gastroenteropancreatic-neuroendocrine-neoplasms-gepnens-at-a-single-institution?format=html [O2] Estrada (POSTER) - Analysis of patient selection for germline testing in early onset gastroenteropancreatic neuroendocrine neoplasms (GEPNENs) at a single institution https://nanets.net/abstracts-archive/2025/2212-o2-estrada-poster-analysis-of-patient-selection-for-germline-testing-in-early-onset-gastroenteropancreatic-neuroendocrine-neoplasms-gepnens-at-a-single-institution?format=html gibsonc@adgcommunications.com (Cassandra Gibson) 2025 Tue, 16 Dec 2025 10:23:07 -0500 https://nanets.net/abstracts-archive/2025/2211-t1-kunz-poster-netter-3-177lu-lu-dota-tate-in-patients-with-newly-diagnosed-grade-1-2-ki-67-10-advanced-gastroenteropancreatic-neuroendocrine-tumors-and-high-disease-burden?format=html [T1] Kunz (POSTER) - NETTER 3 [177Lu]Lu DOTA TATE in patients with newly diagnosed, Grade 1 2 (Ki 67 10%) advanced gastroenteropancreatic neuroendocrine tumors and high disease burden https://nanets.net/abstracts-archive/2025/2211-t1-kunz-poster-netter-3-177lu-lu-dota-tate-in-patients-with-newly-diagnosed-grade-1-2-ki-67-10-advanced-gastroenteropancreatic-neuroendocrine-tumors-and-high-disease-burden?format=html gibsonc@adgcommunications.com (Cassandra Gibson) 2025 Tue, 16 Dec 2025 10:21:58 -0500 https://nanets.net/abstracts-archive/2025/2210-o6-vaca-effect-of-glp-1-receptors-agonists-on-progression-free-survival-in-patients-with-well-differentiated-neuroendocrine-tumors-treated-with-lanreotide-1?format=html [O6] Vaca (POSTER) - Effect of GLP 1 receptors agonists on progression free survival in patients with well differentiated neuroendocrine tumors treated with lanreotide https://nanets.net/abstracts-archive/2025/2210-o6-vaca-effect-of-glp-1-receptors-agonists-on-progression-free-survival-in-patients-with-well-differentiated-neuroendocrine-tumors-treated-with-lanreotide-1?format=html gibsonc@adgcommunications.com (Cassandra Gibson) 2025 Tue, 16 Dec 2025 10:18:10 -0500 https://nanets.net/abstracts-archive/2025/2209-c30-sztangret-poster-disco-safety-tolerability-and-diagnostic-performance-of-64cu-sartate-compared-to-68ga-dotatate-in-patients-with-known-or-suspected-neuroendocrine-tumors?format=html [C30] Sztangret (POSTER) - DISCO Safety, Tolerability and Diagnostic performance of 64Cu SARTATE compared to 68Ga DOTATATE in patients with known or suspected neuroendocrine tumors https://nanets.net/abstracts-archive/2025/2209-c30-sztangret-poster-disco-safety-tolerability-and-diagnostic-performance-of-64cu-sartate-compared-to-68ga-dotatate-in-patients-with-known-or-suspected-neuroendocrine-tumors?format=html gibsonc@adgcommunications.com (Cassandra Gibson) 2025 Tue, 16 Dec 2025 10:17:09 -0500 https://nanets.net/abstracts-archive/2025/2208-p4-sun-poster-survival-of-colorectal-small-cell-carcinoma-and-comparison-with-colorectal-adenocarcinoma?format=html [P4] Sun (POSTER) - Survival of colorectal small cell carcinoma and comparison with colorectal adenocarcinoma https://nanets.net/abstracts-archive/2025/2208-p4-sun-poster-survival-of-colorectal-small-cell-carcinoma-and-comparison-with-colorectal-adenocarcinoma?format=html gibsonc@adgcommunications.com (Cassandra Gibson) 2025 Tue, 16 Dec 2025 10:14:50 -0500 https://nanets.net/abstracts-archive/2025/2207-c33-al-toubah-poster-somatostatin-receptor-expression-on-68ga-dotatate-imaging-among-patients-with-poorly-differentiated-extra-pulmonary-neuroendocrine-carcinomas-a-prospective-study?format=html [C33] Al-Toubah (POSTER) - Somatostatin receptor expression on 68Ga Dotatate imaging among patients with poorly differentiated extra pulmonary neuroendocrine carcinomas a prospective study https://nanets.net/abstracts-archive/2025/2207-c33-al-toubah-poster-somatostatin-receptor-expression-on-68ga-dotatate-imaging-among-patients-with-poorly-differentiated-extra-pulmonary-neuroendocrine-carcinomas-a-prospective-study?format=html gibsonc@adgcommunications.com (Cassandra Gibson) 2025 Tue, 16 Dec 2025 10:12:25 -0500 https://nanets.net/abstracts-archive/2025/2206-c26-koch-poster-clinical-outcomes-following-salvage-prrt-in-patients-with-metastatic-neuroendocrine-tumors?format=html [C26] Koch (POSTER) - Clinical outcomes following salvage PRRT in patients with metastatic neuroendocrine tumors https://nanets.net/abstracts-archive/2025/2206-c26-koch-poster-clinical-outcomes-following-salvage-prrt-in-patients-with-metastatic-neuroendocrine-tumors?format=html gibsonc@adgcommunications.com (Cassandra Gibson) 2025 Tue, 16 Dec 2025 10:10:20 -0500 https://nanets.net/abstracts-archive/2025/2205-p2-zheng-poster-racial-and-ethnic-disparities-in-us-neuroendocrine-tumor-clinical-trial-enrollment-over-the-past-quarter-century?format=html [P2] Zheng (POSTER) - Racial and ethnic disparities in US neuroendocrine tumor clinical trial enrollment over the past quarter century https://nanets.net/abstracts-archive/2025/2205-p2-zheng-poster-racial-and-ethnic-disparities-in-us-neuroendocrine-tumor-clinical-trial-enrollment-over-the-past-quarter-century?format=html gibsonc@adgcommunications.com (Cassandra Gibson) 2025 Tue, 16 Dec 2025 10:08:39 -0500 https://nanets.net/abstracts-archive/2025/2204-t15-chauhan-etctn-10558-a-phase-ii-randomized-control-trial-of-triapine-plus-lutetium-177-dotatate-versus-lutetium-177-dotatate-alone-for-well-differentiated-somatostatin-receptor-positive-neuroendocrine-tumors?format=html [T15] Chauhan - ETCTN 10558 A Phase II Randomized Control Trial of Triapine Plus Lutetium 177 Dotatate Versus Lutetium 177 Dotatate Alone for Well Differentiated Somatostatin Receptor Positive Neuroendocrine Tumors https://nanets.net/abstracts-archive/2025/2204-t15-chauhan-etctn-10558-a-phase-ii-randomized-control-trial-of-triapine-plus-lutetium-177-dotatate-versus-lutetium-177-dotatate-alone-for-well-differentiated-somatostatin-receptor-positive-neuroendocrine-tumors?format=html gibsonc@adgcommunications.com (Cassandra Gibson) 2025 Tue, 09 Dec 2025 16:29:52 -0500